

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM644197

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	INTELLECTUAL PROPERTY SECURITY AGREEMENT		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
XERIS PHARMACEUTICALS, INC.		05/03/2021	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	OXFORD FINANCE LLC, as Collateral Agent		
<b>Street Address:</b>	115 South Union Street, Suite 300		
<b>City:</b>	Alexandria		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22314		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90359515	XERIJECT	
<b>Serial Number:</b>	90359499	XERISOL	
<b>Serial Number:</b>	90165932	GVOKE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	800-494-5225		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Stewart Walsh		
<b>Address Line 1:</b>	1025 Vermont Ave NW, Suite 1130		
<b>Address Line 2:</b>	COGENCY GLOBAL Inc.		
<b>Address Line 4:</b>	Washington, D.C. 20005		
<b>ATTORNEY DOCKET NUMBER:</b>	1366831 TM		
<b>NAME OF SUBMITTER:</b>	ANDREW NASH		
<b>SIGNATURE:</b>	/ANDREW NASH/		
<b>DATE SIGNED:</b>	05/04/2021		
<b>Total Attachments: 14</b>			
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page1.tif			

OP \$90.00 90359515

source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page2.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page3.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page4.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page5.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page6.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page7.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page8.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page9.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page10.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page11.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page12.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page13.tif  
source=Oxford - SVB - Xeris - Intellectual Property Security Agreement - 5.3.2021#page14.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of May 3, 2021 by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (in such capacity, the "Collateral Agent") and XERIS PHARMACEUTICALS, INC., a Delaware corporation with offices located at 180 North LaSalle Street, Suite 1600, Chicago, IL 60601 ("Grantor").

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Amended and Restated Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated as of September 10, 2019 (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:

180 North LaSalle Street, Suite 1600  
Chicago, IL 60601  
Attn: Legal Department

GRANTOR:

XERIS PHARMACEUTICALS, INC.

By: Barry M. Deuterch  
Title: Chief Financial Officer

Address of Lender:

115 South Union Street, Suite 300  
Alexandria, Virginia 22314  
Attn: Legal Department

COLLATERAL AGENT:

OXFORD FINANCE LLC

By: \_\_\_\_\_

Title: \_\_\_\_\_

*[Signature Page to Intellectual Property Security Agreement]*

EAST\180971529

**TRADEMARK**  
**REEL: 007279 FRAME: 0403**

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

180 North LaSalle Street, Suite 1600  
Chicago, IL 60601  
Attn: Legal Department

XERIS PHARMACEUTICALS, INC.

By: \_\_\_\_\_


Title: \_\_\_\_\_

COLLATERAL AGENT:

Address of Lender:

115 South Union Street, Suite 300  
Alexandria, Virginia 22314  
Attn: Legal Department

OXFORD FINANCE LLC

By:  \_\_\_\_\_

Title: Colette H. Featherly, Senior Vice President

*{Signature Page to Intellectual Property Security Agreement}*

EAST\180971529

**TRADEMARK**  
**REEL: 007279 FRAME: 0404**

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

## EXHIBIT B

## Patents

Country	Application Number	Application Date	Patent Number	Grant Date	Title/Full Mark Name
Armenia	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Australia	2012332556	10/31/2012	2012332556	09/08/2016	FORMULATIONS FOR THE TREATMENT OF DIABETES
Australia	2013284412	06/27/2013	2013284412	04/05/2018	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS
Australia	2018275686	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Australia	2018301715	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Australia	2018388417	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Australia	2019211352	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Austria	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Azerbaijan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Azerbaijan	201490913	10/31/2012	027744	08/31/2017	FORMULATIONS FOR THE TREATMENT OF DIABETES
Bahrain	20200009	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Belarus	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS

Brazil	BR11202000447-2	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Brazil	BR112020012268-8	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Brazil	BR112020014719-2	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Canada	3,064,840	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Canada	3,069,533	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
China	201610221799.6	03/09/2012	ZL201610221799.6	08/30/2019		STABLE FORMULATIONS FOR PARENTERAL INJECTION
China	201880036611.8	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
China	201880047057.3	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
China	201880083343.5	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
China	201980009791.5	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Colombia	NC2019/0013342	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Colombia	NC2020/0000529	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM



Denmark	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Denmark	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
EPC - European Patent Convention	21156886.0	08/06/2015			SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES
EPC - European Patent Convention	18733442.0	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
EPC - European Patent Convention	18749686.4	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
EPC - European Patent Convention	18837063.9	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
EPC - European Patent Convention	19196481.6	12/22/2003			FORMULATION FOR INTRACUTANEOUS INJECTION
EPC - European Patent Convention	19704169.2	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
France	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
France	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Germany	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Germany	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Ireland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Israel	270979	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS

Israel	271967	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Italy	12711071.6	03/09/2012	2683364	01/18/2017		STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Japan	2020-173883	08/06/2015				SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES
Japan	2019-566327	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Japan	2020-501203	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Japan	2020-534601	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Japan	(To Be Determined)	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Kazakhstan	201370178	03/09/2012	028572	12/29/2017		STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Korea, Republic of	10-2019-7035678	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Korea, Republic of	10-2020-7020257	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Korea, Republic of	10-2020-7022613	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON

Kyrgyzstan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Mexico	MX/ai/2019/014486	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Mexico	MX/ai/2020/000514	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Mexico	MX/ai/2020/006658	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Mexico	MX/ai/2020/007768	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Moldova, Republic of	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Netherland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
PCT - Patent Cooperation Treaty	PCT/US2020/035172	05/29/2020			STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME

Poland	12798470.6	10/31/2012	2773331	02/10/2016	FORMULATIONS FOR THE TREATMENT OF DIABETES
Qatar	QA/202001/00031	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Russian Federation	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Saudi Arabia	520411047	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Saudi Arabia	520412302	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Saudi Arabia	520412487	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Spain	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Sweden	15706976.6	02/06/2015	3102184	01/30/2019	STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION
Switzerland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION

Tajikistan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Tajikistan	201490913	10/31/2012	027744	08/31/2017	FORMULATIONS FOR THE TREATMENT OF DIABETES
Turkey	12798470.6	10/31/2012	12798470.6	02/10/2016	FORMULATIONS FOR THE TREATMENT OF DIABETES
Turkmenistan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
United Arab Emirates	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
United Arab Emirates	P6000062/20	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
United Kingdom of Great Britain and Northern Ireland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
United States of America	177215,449	03/29/2021			STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
United States of America	16/945,598	07/31/2020			STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS
United States of America	16/600,722	10/14/2019			METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS

United States of America	16/630,774	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
United States of America	16/955,698	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
United States of America	16/964,124	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
United States of America	16/888,028	05/29/2020				STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME
United States of America	63/044,973	06/26/2020				STABLE SUBSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME

## EXHIBIT C

## Trademarks

Mark	Country	Status	Appl. No.	Appl. Date	Reg. No.	Reg. Date
OGLUO	European Union	REGISTERED	18288558	08/12/2020	18288558	01/08/2021
GVOKE logo	International Bureau of the World Intellectual Property Organization (WIPO)	PENDING	A0106151	03/05/2021		
XERIJECT	U.S.	PENDING	90/359,515	12/04/2020		
XERISOL	U.S.	PENDING	90/359,499	12/04/2020		
GVOKE logo	U.S.	PENDING	90/165,932	09/08/2020		
GLUCAXER	United Kingdom	REGISTERED	UK009017884655	04/06/2018	UK009017884655	08/29/2018
GLUCAXER HYOPEN	United Kingdom	REGISTERED	UK009017884652	04/06/2018	UK009017884652	08/29/2018
GVOKE	United Kingdom	REGISTERED	UK0081462300	12/19/2018	UK0081462300	12/19/2018
GVOKE HYOPEN	United	REGISTERED	UK0081462159	12/19/2018	UK0081462159	12/19/2018

Mark	Country	Status	Appl. No.	Appl. Date	Reg. No.	Reg. Date
	Kingdom					
HYOPEN	United Kingdom	REGISTERED	UK009017923552	06/27/2018	UK009017923552	11/29/2018
XERIJECT	United Kingdom	REGISTERED	UK009017459199	11/10/2017	UK009017459199	03/12/2018
XERISOL	United Kingdom	REGISTERED	UK009017459173	11/10/2017	UK009017459173	03/12/2018
OGLUO	United Kingdom	REGISTERED	3521904	08/12/2020	3521904	11/27/2020